Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

218,661 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Six versus four or five cycles of first-line etoposide and platinum-based chemotherapy combined with thoracic radiotherapy in patients with limited-stage small-cell lung cancer: A propensity score-matched analysis of a prospective randomized trial.
Yu TT, Hu X, Liufu WJ, Niu SQ, Lian HM, Ma HL, Wang J, Bao Y, Chen M, Peng F. Yu TT, et al. Among authors: wang j. Cancer Med. 2024 Apr;13(8):e7215. doi: 10.1002/cam4.7215. Cancer Med. 2024. PMID: 38659392 Free PMC article. Clinical Trial.
Sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-stage small cell lung cancer: a phase II clinical trial.
Han X, Guo J, Li L, Huang Y, Meng X, Wang L, Zhu H, Meng X, Shao Q, Li X, Zhang Y, Wang J, Chen Y, Zhang Y, Chen Y, Zhu C, Wang Z. Han X, et al. Among authors: wang l, wang j, wang z. Signal Transduct Target Ther. 2024 Sep 16;9(1):241. doi: 10.1038/s41392-024-01957-3. Signal Transduct Target Ther. 2024. PMID: 39278918 Free PMC article. Clinical Trial.
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.
Schuler M, Yang JC, Park K, Kim JH, Bennouna J, Chen YM, Chouaid C, De Marinis F, Feng JF, Grossi F, Kim DW, Liu X, Lu S, Strausz J, Vinnyk Y, Wiewrodt R, Zhou C, Wang B, Chand VK, Planchard D; LUX-Lung 5 Investigators. Schuler M, et al. Among authors: wang b. Ann Oncol. 2016 Mar;27(3):417-23. doi: 10.1093/annonc/mdv597. Epub 2015 Dec 8. Ann Oncol. 2016. PMID: 26646759 Free PMC article. Clinical Trial.
Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial.
Peters S, Dziadziuszko R, Morabito A, Felip E, Gadgeel SM, Cheema P, Cobo M, Andric Z, Barrios CH, Yamaguchi M, Dansin E, Danchaivijitr P, Johnson M, Novello S, Mathisen MS, Shagan SM, Schleifman E, Wang J, Yan M, Mocci S, Voong D, Fabrizio DA, Shames DS, Riehl T, Gandara DR, Mok T. Peters S, et al. Among authors: wang j. Nat Med. 2022 Sep;28(9):1831-1839. doi: 10.1038/s41591-022-01933-w. Epub 2022 Aug 22. Nat Med. 2022. PMID: 35995953 Free PMC article. Clinical Trial.
Safety and feasibility of neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced esophageal squamous cell carcinoma: a prospective single-group phase II clinical study.
Cheng L, Wang X, Shen H, Wang J, Yang Y, Wu W, Mehmood R, Shen D, Jiang Y, Ji Y. Cheng L, et al. Among authors: wang x, wang j. J Thorac Dis. 2024 Oct 31;16(10):7029-7041. doi: 10.21037/jtd-24-1279. Epub 2024 Oct 17. J Thorac Dis. 2024. PMID: 39552849 Free PMC article.
Tislelizumab in previously treated, locally advanced unresectable/metastatic microsatellite instability-high/mismatch repair-deficient solid tumors.
Li J, Xu Y, Zang A, Gao Y, Gao Q, Zhang Y, Wang D, Xu J, Yuan Y, Jiang H, Ying J, Shi C, Deng Y, Wang J, Liu T, Huang Y, Qian X, Pan Y, Cheng Y, Hu S, Wang J, Shi M, Wang K, Hu H, Shen L. Li J, et al. Among authors: wang k, wang j, wang d. Chin J Cancer Res. 2024 Jun 30;36(3):257-269. doi: 10.21147/j.issn.1000-9604.2024.03.03. Chin J Cancer Res. 2024. PMID: 38988490 Free PMC article.
Efficacy and safety of JMT103 in patients with unresectable or surgically-challenging giant cell tumor of bone: a multicenter, phase Ib/II study.
Xu H, Zhou Y, Liang L, Shen J, Yan W, Wang J, Li J, Zhang X, Huang G, Bi W, Guo Z, Xiao Y, Lin J, Yao W, Tong Z, Zhou W, Zhang G, Ye Z, Wang D, Yang J, Fan Z, Liu C, Qu G, Zhang Q, Wei F, Liu W, Tu C, Li H, Yuan J, Niu X. Xu H, et al. Among authors: wang j, wang d. Nat Commun. 2024 Nov 5;15(1):9541. doi: 10.1038/s41467-024-53686-4. Nat Commun. 2024. PMID: 39500883 Free PMC article. Clinical Trial.
A novel anti-HER2 monoclonal antibody IAH0968 in HER2-positive heavily pretreated solid tumors: results from a phase Ia/Ib first-in-human, open-label, single center study.
Song N, Teng Y, Shi J, Teng Z, Jin B, Qu J, Zhang L, Yu P, Zhao L, Wang J, Li A, Tong L, Jiang S, Liu Y, Yin L, Jiang X, Xu T, Cui J, Qu X, Liu Y. Song N, et al. Among authors: wang j. Front Immunol. 2024 Nov 29;15:1481326. doi: 10.3389/fimmu.2024.1481326. eCollection 2024. Front Immunol. 2024. PMID: 39676868 Free PMC article. Clinical Trial.
218,661 results
You have reached the last available page of results. Please see the User Guide for more information.